These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 22706484)

  • 61. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
    Minniti G; De Sanctis V; Muni R; Filippone F; Bozzao A; Valeriani M; Osti MF; De Paula U; Lanzetta G; Tombolini V; Maurizi Enrici R
    J Neurooncol; 2008 May; 88(1):97-103. PubMed ID: 18250965
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
    Saran F; Chinot OL; Henriksson R; Mason W; Wick W; Cloughesy T; Dhar S; Pozzi E; Garcia J; Nishikawa R
    Neuro Oncol; 2016 Jul; 18(7):991-1001. PubMed ID: 26809751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
    Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J
    J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
    Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
    Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
    Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6767-71. PubMed ID: 16203762
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
    Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
    Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
    Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
    J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.
    Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL
    J Neurooncol; 2004; 67(1-2):191-200. PubMed ID: 15072467
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
    Nabors LB; Fiveash JB; Markert JM; Kekan MS; Gillespie GY; Huang Z; Johnson MJ; Meleth S; Kuo H; Gladson CL; Fathallah-Shaykh HM
    Arch Neurol; 2010 Mar; 67(3):313-9. PubMed ID: 20212229
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Invasion is not an independent prognostic factor in high-grade glioma.
    Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
    J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Potential usefulness of radiosensitizers in glioblastoma.
    Harasaki Y; Waziri A
    Neurosurg Clin N Am; 2012 Jul; 23(3):429-37. PubMed ID: 22748655
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
    Ho J; Ondos J; Ning H; Smith S; Kreisl T; Iwamoto F; Sul J; Kim L; McNeil K; Krauze A; Shankavaram U; Fine HA; Camphausen K
    PLoS One; 2013; 8(8):e70745. PubMed ID: 23940635
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.